ArticleACS medicinal chemistry letters2012

SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

John Wityak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.